Help Patients Stick With a Statin...Instead of the New PCSK9 Inhibitors

October 2015

The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin.

Repatha is similar to Praluent (alirocumab).

Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote